Company intelligence / Profile preview
Nohla Therapeutics
Seattle, Washington, United Statesx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Nohla developed dilanubicel, a universal off-the-shelf stem and progenitor cell therapy that was in Phase 2 trials for patients with hematologic malignancies undergoing allogeneic transplant and AML patients with chemotherapy-induced myelosuppression. Early clinical trials showed reduced rates of acute graft-versus-host disease and transplant-related mortality while enhancing hematopoietic recovery.
- Therapeutic areas
- Oncology
- Modalities
- Cellular therapiesex vivo expanded umbilical cord bloodstem and progenitor cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Fred Hutchinson Cancer Research Center
Beyond the preview
Go deeper on Nohla Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nohla Therapeutics.